Cannabis Science Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with Its Team of FDA Specialists

COLORADO SPRINGS, Colo. – Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce its FDA progress resulting from the last meeting with the Company’s FDA Specialist team to officially determine that the target indication will be for a topical application for skin cancer.

Cannabis Science has already seen first hand success in reducing the tumor burden in basil and squamous cell carcinoma, two forms of skin cancer. The company website http://cannabisscience.com photo-documents tumor shrinkage and disappearance after the self-administration of topical cannabis extract treatment by four skin cancer patients. As a consequence of these anecdotal observations, Cannabis Science is confident of the need and opportunity to enter the prescription drug market. Our advisors are preparing the required submission for a pre-IND application to the FDA for our topical skin cream/extract for skin cancer.

Cannabis Science is excited to pursue these investigations with the help of our FDA specialists. Cannabis Science is overseeing additional successes with other self-medicating cancer patients suffering from a variety of other cancers. Reports of their progress will be made available as treatments progress and are confirmed.

via : businesswire

VN:F [1.9.22_1171]
Rating: 7.8/10 (5 votes cast)
VN:F [1.9.22_1171]
Rating: +3 (from 7 votes)
Cannabis Science Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with Its Team of FDA Specialists, 7.8 out of 10 based on 5 ratings

Leave a Reply

You must be logged in to post a comment.